



Complix is a biopharmaceutical company developing a pipeline of therapeutics, called Alphabodies™, mainly focused on oncology and autoimmunity. Alphabodies are a revolutionary class of protein therapeutics that combine the attractive features of antibodies, including high target specificity and affinity, with the benefits from small chemical drugs such as extreme stability and their capacity to penetrate cells. As a result of these unique features, Alphabodies can tackle a broad range of diseases where treatment options today are limited or non-existent.

Complix is headquartered in Hasselt (Belgium) at the Life Sciences incubator BioVille, and has research facilities in Ghent (Belgium) and in Luxembourg.

## Überblick

<b>Aktivität</b>	Discovery and development of novel therapeutics based on Alphabodies™
<b>Land</b>	Belgien
<b>Investitionsjah</b>	2013
<b>Plattform</b>	Health & Care
<b>Mitarbeiter</b>	20
<b>Website</b>	<a href="http://www.complix.be">www.complix.be</a>

